These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 6993401)

  • 1. Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics.
    Abi-Dargham A
    J Psychiatr Brain Sci; 2021; 6():. PubMed ID: 34532594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.
    Clark SD; Van Snellenberg JX; Lawson JM; Abi-Dargham A
    Neuropsychopharmacology; 2020 Oct; 45(11):1860-1869. PubMed ID: 32516800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WIN 44,441: A Stereospecific and Long-Acting Narcotic Antagonist.
    Wood PL; Pilapil C; Thakur M; Richard JW
    Pharm Res; 1984 Jan; 1(1):46-8. PubMed ID: 24277186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of naltrexone in the treatment of schizophrenia.
    Gitlin MJ; Gerner RH; Rosenblatt M
    Psychopharmacology (Berl); 1981; 74(1):51-3. PubMed ID: 6791204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic role of naltrexone in negative symptom schizophrenia.
    Marchesi GF; Santone G; Cotani P; Giordano A; Chelli F
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Dec; 19(8):1239-49. PubMed ID: 8868206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of naltrexone on mannerisms and water imbalance in polydipsic schizophrenics: a pilot study.
    Becker JA; Goldman MB; Alam MY; Luchins DJ
    Schizophr Res; 1995 Nov; 17(3):279-82. PubMed ID: 8664207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone in chronic negative schizophrenia.
    Marchesi GF; Santone G; Cotani P; Giordano A; Chelli F
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():56A-57A. PubMed ID: 1498948
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study.
    Pickar D; Vartanian F; Bunney WE; Maier HP; Gastpar MT; Prakash R; Sethi BB; Lideman R; Belyaev BS; Tsutsulkovskaja MV; Jungkunz G; Nedopil N; Verhoeven W; van Praag H
    Arch Gen Psychiatry; 1982 Mar; 39(3):313-9. PubMed ID: 6121545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone in chronic schizophrenia. Results of a clinical trial.
    Ragheb M; Berney S; Ban T
    Int Pharmacopsychiatry; 1980; 15(1):1-5. PubMed ID: 6993401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opiate antagonists for the treatment of schizophrenia.
    Welch EB; Thompson DF
    J Clin Pharm Ther; 1994 Oct; 19(5):279-83. PubMed ID: 7806598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the National Academy of Sciences study of naltrexone.
    Kaim SC
    NIDA Res Monogr; 1976 Sep; (9):37-44. PubMed ID: 794719
    [No Abstract]   [Full Text] [Related]  

  • 12. NIDA's naltrexone research program.
    Julius D
    NIDA Res Monogr; 1976 Sep; (9):5-11. PubMed ID: 187943
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.